Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00611026 |
To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder
Condition | Intervention | Phase |
---|---|---|
Overactive Bladder |
Drug: Tolterodine ER Drug: Placebo Drug: Fesoterodine |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study |
Official Title: | 12-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Comparison To Tolterodine ER In Patients With Overactive Bladder. |
Estimated Enrollment: | 1675 |
Study Start Date: | February 2008 |
Estimated Study Completion Date: | August 2009 |
Estimated Primary Completion Date: | August 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator |
Drug: Tolterodine ER
The tolterodine treatment will be 4 mg QD for 12 weeks.
|
2: Placebo Comparator |
Drug: Placebo
Placebo treatment will be QD for 12 weeks.
|
3: Experimental |
Drug: Fesoterodine
The fesoterodine treatment will start with 4 mg QD for 1 week followed by a forced dose-escalation to 8mg QD for 11 weeks.
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Pfizer CT.gov Call Center | 1-800-718-1021 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer Inc ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A0221046 |
Study First Received: | January 28, 2008 |
Last Updated: | January 9, 2009 |
ClinicalTrials.gov Identifier: | NCT00611026 |
Health Authority: | United States: Food and Drug Administration |
Treatment of overactive bladder |
Signs and Symptoms Urinary Bladder, Overactive Cystocele |
Urologic Diseases Urinary Bladder Diseases Tolterodine |
Muscarinic Antagonists Urological Manifestations Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |
Cholinergic Antagonists Physiological Effects of Drugs Cholinergic Agents Pharmacologic Actions |